Evidence map›Paper›PMID 30312275›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2018

Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine.

Alyona Mazhnaya, Ruthanne Marcus, Martha J Bojko, Alexei Zelenev, Iuliia Makarenko, Iryna Pykalo, Sergii Filippovych, Sergii Dvoriak, Frederick L Altice

Open access · greenAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Alyona MazhnayaTreatment, Procurement and Supply Management Department, International Charitable Foundation "Alliance for Public Health", Kyiv, Ukraine.
Ruthanne MarcusAIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Martha J BojkoAIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Alexei ZelenevAIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Iuliia MakarenkoTreatment, Procurement and Supply Management Department, International Charitable Foundation "Alliance for Public Health", Kyiv, Ukraine.
Iryna PykaloUkrainian Institute on Public Health Policy, Kyiv, Ukraine.
Sergii FilippovychTreatment, Procurement and Supply Management Department, International Charitable Foundation "Alliance for Public Health", Kyiv, Ukraine.
Sergii DvoriakUkrainian Institute on Public Health Policy, Kyiv, Ukraine.
Frederick L AlticeDivision of Epidemiology of Microbial Diseases, Yale University School of Public Health, New Haven, CT.
Yale University · USAlliance for Public Health · UAUkrainian Institute of Public Health Policy · UAJohns Hopkins University · US

Funding

Research Mentoring and Building Capacity of underrepresented Minority Research Scientists in India.D43TW010540 · FIC · YALE UNIVERSITY · PI MICHELE BARRY, Eva Harris · 2017 to 2026
$15.5M
Training in the Epidemiology of HPV/Cervical Neoplasia Among HIV+ WomenD43TW000233 · FIC · SUNY DOWNSTATE MEDICAL CENTER · PI DEHOVITZ, JACK A · 1993 to 2015
$10.1M
Prison Interventions and HIV Prevention CollaborationR01DA029910 · NIDA · YALE UNIVERSITY · PI FREDERICK LEWIS ALTICE · 2010 to 2026
$7.9M
Expanding Medication Assisted Therapy in Ukraine (ExMAT)R01DA033679 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2012 to 2021
$6.4M
Global Health Fellows and Scholars Research TrainingR25TW009338 · FIC · UNIVERSITY OF CALIFORNIA BERKELEY · PI BARRY, MICHELE, KO, ALBERT ICKSANG · 2012 to 2016
$5.2M
Integrating Addiction Treatment and HIV Services into Primary Care Clinics in UkraineR01DA043125 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2016 to 2021
$4.4M
Network-based epidemiology for hidden and hard-to-reach populationsDP2HD091799 · NICHD · YALE UNIVERSITY · PI CRAWFORD, FORREST WRENN · 2016 to 2016
$2.5M
Enhancing Health Outcomes Among HIV+ Substance AbusersK24DA017072 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2003 to 2012
$1.5M
Modeling HIV & Substance Abuse: Correcting Sampling Bias and Cost EffectivenessK01DA037826 · NIDA · YALE UNIVERSITY · PI ZELENEV, ALEXEI · 2014 to 2018
$838k
FIC NIH HHS D43 TW000233FIC NIH HHS D43 TW010540FIC NIH HHS R25 TW009338NICHD NIH HHS DP2 HD091799NIDA NIH HHS K01 DA037826NIDA NIH HHS K24 DA017072NIDA NIH HHS R01 DA029910NIDA NIH HHS R01 DA033679NIDA NIH HHS R01 DA043125
6 · The paper itself

Abstract

backgroundThe HIV treatment cascade is a crucial tool to guide HIV prevention and treatment strategies. The extent to which opioid agonist treatments (OATs) such as methadone and buprenorphine influence this cascade was examined in a nationwide study of people who inject drugs (PWID) in Ukraine.

settingCross-sectional stratified survey of PWID followed by HIV and hepatitis C virus testing in 5 Ukrainian cities.

methodsOpioid-dependent PWID (N = 1613) were sampled from January 2014 to March 2015. Analysis was confined to 520 participants with HIV, with 184 (35.4%) prescribed OAT. Weighted logistic regression models were used to assess independent factors associated with the 5 steps in the HIV treatment cascade.

resultsCompared with PWID not on OAT (N = 336), participants who prescribed OAT (N = 184) were significantly more likely to be diagnosed (91% vs. 71%), linked (81% vs. 52%), and retained (69% vs. 35%) in HIV care, and prescribed (56% vs. 31%) and optimally (>95% of doses) adherent to antiretroviral therapy (41% vs. 22%). Receiving OAT contributed most as an independent factor with every step of the cascade. Other steps in the HIV treatment cascade were influenced by age, depression, and geographical variability.

conclusionsOAT remains an essential and effective strategy to not only treat patients with opioid use disorder, but also a crucial strategy to engage PWID in care to meet UNAIDS 90-90-90 targets. Geographical differences suggest local structural impediments. With low OAT coverage prescribed for 2.9% of the estimated 347,000 PWID in Ukraine, OAT expansion requires strategic interventions that target the individual, clinical care settings, policies, and funding.

Indexed as

AdolescentAdultAgedAnalgesics, OpioidAnti-HIV AgentsBuprenorphineCitiesCross-Sectional StudiesFemaleHIV InfectionsHumansMaleMethadoneMiddle AgedSubstance Abuse, IntravenousTreatment OutcomeAnalgesics, OpioidAnti-HIV AgentsBuprenorphineMethadone

Identifiers

PMID30312275
PMCPMC8215524
OpenAlexW2895909318

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.